Japanese researchers at RIKEN and Organ Technologies have unveiled a groundbreaking discovery: a previously unidentified 'third cell' in adult hair follicles that is crucial for complete hair regeneration. Dubbed the 'hair follicle regeneration support cell,' this novel cell type, when combined with epithelial stem cells and dermal papilla-derived cells, enables the creation of fully functional hair follicles in vitro that cycle through growth phases and produce hair in mice models. This advancement, published today in Biochemical and Biophysical Research Communications (DOI: 10.1016/j.bbrc.2026.153459), holds immense promise for treating alopecia conditions like androgenetic alopecia and alopecia areata, which affect millions in Japan.

In Japan, where alopecia areata prevalence hovers around 2%—equating to over 2.5 million people—and androgenetic alopecia impacts up to 26% of men and 19% of women over 50, current treatments like minoxidil and finasteride offer limited success rates, often below 40% for sustained regrowth. This discovery could revolutionize regenerative medicine by providing a minimal set of adult-derived stem cells capable of reconstructing hair follicles from scratch, bypassing donor limitations in transplants.

🔬 Decoding Hair Follicle Biology: From Bulge to Regeneration

Hair follicles, the mini-organs responsible for hair production, undergo cyclic phases: growth (anagen), regression (catagen), and rest (telogen). Quiescent stem cells reside in the bulge region at the follicle's base, while more active progenitors form the hair germ below. Dermal papilla cells orchestrate signaling to trigger growth. However, complete regeneration has eluded scientists because merely combining bulge epithelial stem cells and dermal papilla cells resulted in incomplete follicles that failed long-term cycling after transplantation.

Observations in mouse skin grafts revealed a missing piece: surrounding cells migrated to support full downgrowth and pigmentation. The research team, using advanced cell sorting and single-cell RNA sequencing, isolated the elusive 'hair follicle regeneration support cell' from adult vibrissae (whisker) follicles. These mesenchymal-like cells express unique markers, promoting matrix cell proliferation and bulb formation essential for the anagen phase.

• Epithelial stem cells (bulge-derived): Provide the outer root sheath and matrix progenitors.
• Dermal papilla-induced cells: Signal for follicle induction and vascularization.
• Hair follicle regeneration support cells (third cell): Stabilize the niche, enabling sustained cycling and downgrowth.

This trio forms the 'hair follicle organ primordium'—a bioengineered germ that, in culture, develops a proper hair bulb and shaft, mimicking natural physiology step-by-step: placode formation (day 1-3), downgrowth (day 5-7), and pigmentation (day 10+).

RIKEN's Pioneering Legacy in Organ Regeneration

RIKEN's Center for Biosystems Dynamics Research (BDR), under former team leader Takashi Tsuji, has led hair regeneration since 2012 with the 'organ germ method'—culturing embryonic-like primordia from dissociated cells. Milestones include 2016's Kyocera partnership for commercialization and 2021's identification of label-retaining cells (Lgr5+ bulge stem cells) for cyclical grafts. Tsuji, now OrganTech chairman, bridged academia and industry, amplifying cells over 100-fold while preserving potency.

The 2026 study builds on this, shifting to adult cells for ethical, autologous therapies. In mice, primordia transplanted into skin regenerated pigmented, cycling follicles for multiple anagen phases—unlike prior two-cell versions that stalled.

This positions RIKEN as a regenerative medicine hub, fostering collaborations with universities like Tokyo University on iPS-derived follicles.

Organ Technologies: From Lab to Clinic

OrganTech, spun from Tsuji's work, specializes in bio-hybrid organs. R&D Director Kiei Toyoshima and CTO Miho Ogawa led cell isolation using fluorescence-activated sorting and proprietary media. Their culture system yields primordia viable for 30+ days in vitro, with 80% forming mature follicles—doubling prior efficiencies.

Plans include human trials by late 2026-2027, injecting support cells into balding scalps to reactivate dormant follicles. Preclinical safety data supports IND filing soon. For researchers eyeing higher ed research jobs in Japan, OrganTech exemplifies startup-academia synergy.

Experimental Breakthrough: Methods and Mouse Model Results

Adult C57BL/6 mouse vibrissae were dissociated; cells sorted via CD34/CD49f for epithelial stems, Lgr5 for papilla derivatives, and novel SCA-1+/PDGFRα+ for support cells. Co-cultured in Matrigel with FGF/Wnt agonists, primordia self-organized into downgrowing follicles by day 14, producing keratinized shafts.

Transplanted into nude mouse skin, 70% engrafted, cycling thrice over 6 months with normal pigmentation and sebum. Without the third cell, grafts showed 40% failure in bulb formation. Histology confirmed ECM remodeling unique to the support cell's secretome.

This validates the 'minimal stem cell set' for scalable therapies.

Transforming Alopecia Treatment Landscape

Androgenic alopecia (pattern baldness) shrinks follicles via DHT; alopecia areata is autoimmune. Current options: topicals (30% efficacy), transplants (limited donors). The third cell could reprogram miniaturized follicles, offering permanent regrowth.

In Japan, rising AA cases (0.16% to 0.27% 2012-2019) strain dermatology. Support cells might modulate immunity, per Tsuji's vision. Compared to JAK inhibitors (60% patchy regrowth), this targets root cause.

Cultural context: Hair holds social significance in Japan; solutions could boost mental health, reducing associated depression risks by 20-30%.

Challenges, Safety, and Path to Human Trials

• Safety: No teratomas in mice; GMP scaling needed.
• Scalability: Adult cells amplify 200x vs. embryonic.
• Human translation: Phase I dosing 2027, targeting 10^6 cells/cm².

Risks include off-target growth; mitigated by transient support cell use. Regulatory nod via Japan's conditional approval for regeneratives accelerates timeline.

Japan's Regenerative Medicine Ecosystem

Japan leads with 2014 ACT law, funding ¥100B+ annually. RIKEN-OrganTech exemplifies iPS-hair synergy with Kyoto U. For Japan research positions, stem cell labs boom, with 5,000+ postdocs needed by 2030.

Global impact: Exports tech to alopecia markets (US$10B global).

Career Opportunities in Stem Cell Research

This discovery spotlights demand for bioengineers, cell biologists in Japan. RIKEN posts 200+ roles yearly; OrganTech expands. Explore faculty jobs or career advice for regenerative fields.

Photo by Clément ROY on Unsplash

Future Horizons: Beyond Hair to Whole-Organ Regen

Tsuji's lab eyes teeth, skin next. For alopecia sufferers, hope dawns: permanent, natural hair via one's cells. Stay updated via Rate My Professor for Tsuji-inspired mentors, or higher ed jobs in biotech. Japan reaffirms its regenerative prowess.

Check RIKEN press release and full paper.